Literature DB >> 16957979

Exploratory thoracotomy and its influence on the survival of patients with lung cancer.

Lucka Debevec1, Janez Erzen, Andrej Debeljak, Anton Crnjac, Viljem Kovac.   

Abstract

PURPOSE: To evaluate diagnostic procedures, reasons for exploratory thoracotomy (ET), causes of unresectability of lung cancer, possibility for reducing numbers of ETs, and the influence of ET on survival. PATIENTS AND METHODS: Between 1990 and 1999, 1808 patients with lung cancer were operated on. ET was performed in 165 (9.1%) of these cases. In total, 131 ET patients were evaluable for analysis. The clinical stages were: three patients in stage IA, 28 in IB, one in IIA, 35 in IIB, 50 in IIIA, 10 in IIIB (all due to invasion of the mediastinum), and four patients in IV (three with ipsilateral pulmonary and one with solitary suprarenal metastasis). The control group for calculating survival difference consisted of 130 consecutive non-operated patients with comparable characteristics (age, sex, clinical stage, performance status, histology and comorbidity) who were diagnosed during the period 1996-1998.
RESULTS: The diagnostic procedure before ET comprised bronchoscopy in all patients, transthoracic needle biopsy in 13, cervical mediastinoscopy in nine, parasternal mediastinotomy in two and thoracoscopy in two, in all patients without proving unresectability. A CT scan was performed in 118 patients indicating resectability in 33%, doubtful resectability in 64% and unresectability in 3%. Clinical and surgical staging were equal in 3% of stage IIB patients, in 24% of stage IIIA, 100% of stage IIIB and 75% of patients in stage IV. The 30-day operative mortality was 4.6%. The reasons for ET were: diagnosis of preoperatively unverified tumor in one patient, necessity for pneumonectomy in the case of poor pulmonary function in 11 patients, and unresectability in 119 (due to invasion of the mediastinum in 98 patients, thoracic wall in three and vertebral body in one, and due to pleural metastases in 17 patients). ET could have been avoided in 15 (11%) patients. The median survival for both ET and control group patients was 11.1 months. The survival difference was not statistically significant (p = 0.420).
CONCLUSION: ET could be partly avoided through a more accurate preoperative staging procedure. It does not appear possible to avoid ET in patients with limited pulmonary reserve precluding a resection larger than that predicted, nor to avoid ET as a consequence of intraoperative complications. Despite operative mortality, ET did not significantly influence the survival rate in the present study.

Entities:  

Mesh:

Year:  2006        PMID: 16957979     DOI: 10.1007/s00508-006-0638-6

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  22 in total

1.  Clinical experience in staging of lung cancer at Martin-Luther University Halle-Wittenberg.

Authors:  H Neef
Journal:  Ann Ital Chir       Date:  1999 Nov-Dec       Impact factor: 0.766

2.  [Exploratory thoracotomy in surgery of lung cancer].

Authors:  Y E Demidtschik; W W Zharkov; N A Artiemova
Journal:  Zentralbl Chir       Date:  1988       Impact factor: 0.942

3.  [Exploratory thoracotomy of necessity in surgery of bronchial cancer].

Authors:  G Morand; N Roeslin
Journal:  Ann Chir       Date:  1990

4.  [Surgical treatment of lung cancer in Denmark in 1982-1986. Special attention to the surgical procedure and mortality].

Authors:  P E Haahr; L I Andersen; K Andersen
Journal:  Ugeskr Laeger       Date:  1991-06-03

5.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

Review 6.  [Justifications and benefits of exploratory thoracotomy in stage IIIb bronchopulmonary cancer].

Authors:  P Bergeron; J P Martelet; P Casanova; P Rudondy; J Nazet; A Henric; A Puisais-Hee; H Longefait
Journal:  Ann Chir       Date:  1990

7.  Problems in diagnosis and surgical management of clinical N1 non-small cell lung cancer.

Authors:  Shun-ichi Watanabe; Hisao Asamura; Kenji Suzuki; Ryosuke Tsuchiya
Journal:  Ann Thorac Surg       Date:  2005-05       Impact factor: 4.330

Review 8.  Four decades of surgery for bronchogenic carcinoma in one centre.

Authors:  A Spiliopoulos; M de Perrot
Journal:  Eur Respir J       Date:  2000-03       Impact factor: 16.671

9.  Exploratory thoracotomy for nonresectable lung cancer.

Authors:  S S Steinbaum; I D Uretzky; H P McAdams; K G Torrington; A J Cohen
Journal:  Chest       Date:  1995-04       Impact factor: 9.410

10.  [Significance of explorative thoracotomy in the diagnosis and symptomatic treatment of bronchogenic carcinoma].

Authors:  M Rusca; P Soliani; L Cattelani; M Covizzi
Journal:  Acta Biomed Ateneo Parmense       Date:  1989
View more
  2 in total

1.  Unexpected extensions of non-small-cell lung cancer diagnosed during surgery: revisiting exploratory thoracotomies and incomplete resections.

Authors:  Christophe Foucault; Pierre Mordant; Bertrand Grand; Karima Achour; Alex Arame; Antoine Dujon; Françoise Le Pimpec Barthes; Marc Riquet
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-01-23

2.  Release of growth factors after mechanical and chemical pleurodesis for treatment of malignant pleural effusion: a randomized control study.

Authors:  Aljaz Hojski; Maja Leitgeb; Anton Crnjac
Journal:  Radiol Oncol       Date:  2015-11-27       Impact factor: 2.991

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.